{"id":{"repo_id":"buffalo","oai_identifier":"oai:ubir.buffalo.edu:10477/79848"},"canonical_url":"https://search.dev.ndltd.org/etd/buffalo/oai:ubir.buffalo.edu:10477/79848","repository":{"repo_id":"buffalo","name":"Buffalo","base_url":"https://ubir.buffalo.edu/oai/request"},"display":{"title":"Composition-Activity Analyses and Nucleic Acid Loading Strategies for Therapeutic Extracellular Vesicles","abstract":"Ph.D.","abstract_html":"Ph.D.","abstract_has_math":false,"creators":["Ferguson, Scott; 0000-0003-0244-8856"],"institution":"State University of New York at Buffalo","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Nguyen, Juliane","Pharmaceutical Sciences"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-07-29T20:54:59Z","date_published":"2019-07-29T20:54:59Z","updated_at":"2026-07-27T19:05:19Z","subjects":["pharmaceutical sciences"],"languages":["eng"],"rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10477/79848","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Nguyen, Juliane","Pharmaceutical Sciences"]},{"key":"dc:creator","label":"Author","values":["Ferguson, Scott; 0000-0003-0244-8856"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2019-07-29T20:54:59Z","2019","2019-05-08 13:22:50"]},{"key":"dc:publisher","label":"Institution","values":["State University of New York at Buffalo"]},{"key":"dc:type","label":"Dc Type","values":["Text","Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["pharmaceutical sciences"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/10477/79848"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Ph.D.","Exosomes or small extracellular vesicles (EVs) are lipid vesicles - typically 50-150 nm in size -that are released by cells and exert phenotypic effects on recipient cells through signaling or transfer of protein, nucleic acid cargo, and lipids. Since EVs act as natural delivery vehicles of bioactive molecules, there is growing interest to use them therapeutically. The therapeutic use of EVs can encompass unmodified vesicles or engineered vesicles. Unmodified EVs such as those released by stem cells show intrinsic regenerative potential in a number of injury models including ischemia/reperfusion in kidneys, fibrosis of the liver, and myocardial infarction. Engineering of EVs includes surface modifications with targeting ligands, cargo augmentation, and loading with therapeutic compounds. Owing to their biological sourcing, even engineered EVs will retain intrinsic biological activity, which can be difficult to predict. Since EVs also exert potent effectsunder pathophysiological and physiological conditions, understanding the biogenesis and molecular composition of EVs that could potentially result in deleterious effects is critically important. Despite tremendous progress in the engineering of EVs for therapeutic applications, a number of challenges toward clinical translation remain including inefficient cargo loading, andEV heterogeneity. In conclusion, this dissertation provides important advancements toward the potential translation of EVs as therapeutic modalities. First, EV effects were successfully predicted through miRNA-profiling and pathway analysis. These kinds of predictions will be instrumental in understanding EV biology and predicting unwanted side effects. Second, new RNA sequences, EXO-Codes, were discovered that can be used to increase the loading of nucleic acids into EVs. In the larger goal of systemic RNAi or gene therapies using EVs, engineered EVs with increased potency have the potential to deliver on this promise."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Composition-Activity Analyses and Nucleic Acid Loading Strategies for Therapeutic Extracellular Vesicles"]}]}],"canonical_facts":{"dc:contributor":["Nguyen, Juliane","Pharmaceutical Sciences"],"dc:creator":["Ferguson, Scott; 0000-0003-0244-8856"],"dc:date":["2019-07-29T20:54:59Z","2019","2019-05-08 13:22:50"],"dc:description":["Ph.D.","Exosomes or small extracellular vesicles (EVs) are lipid vesicles - typically 50-150 nm in size -that are released by cells and exert phenotypic effects on recipient cells through signaling or transfer of protein, nucleic acid cargo, and lipids. Since EVs act as natural delivery vehicles of bioactive molecules, there is growing interest to use them therapeutically. The therapeutic use of EVs can encompass unmodified vesicles or engineered vesicles. Unmodified EVs such as those released by stem cells show intrinsic regenerative potential in a number of injury models including ischemia/reperfusion in kidneys, fibrosis of the liver, and myocardial infarction. Engineering of EVs includes surface modifications with targeting ligands, cargo augmentation, and loading with therapeutic compounds. Owing to their biological sourcing, even engineered EVs will retain intrinsic biological activity, which can be difficult to predict. Since EVs also exert potent effectsunder pathophysiological and physiological conditions, understanding the biogenesis and molecular composition of EVs that could potentially result in deleterious effects is critically important. Despite tremendous progress in the engineering of EVs for therapeutic applications, a number of challenges toward clinical translation remain including inefficient cargo loading, andEV heterogeneity. In conclusion, this dissertation provides important advancements toward the potential translation of EVs as therapeutic modalities. First, EV effects were successfully predicted through miRNA-profiling and pathway analysis. These kinds of predictions will be instrumental in understanding EV biology and predicting unwanted side effects. Second, new RNA sequences, EXO-Codes, were discovered that can be used to increase the loading of nucleic acids into EVs. In the larger goal of systemic RNAi or gene therapies using EVs, engineered EVs with increased potency have the potential to deliver on this promise."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/10477/79848"],"dc:language":["eng"],"dc:publisher":["State University of New York at Buffalo"],"dc:rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"dc:subject":["pharmaceutical sciences"],"dc:title":["Composition-Activity Analyses and Nucleic Acid Loading Strategies for Therapeutic Extracellular Vesicles"],"dc:type":["Text","Dissertation"]},"updated_at":"2026-07-27T19:05:19Z"}